Outcome and follow-up
The patient first received eculizumab in 2019, which significantly improved and stabilized his condition as assessed by several pertinent physician- and patient-reported outcome measures of MG symptoms and severity and QoL (Besinger, quantitative MG [QMG], MG activities of daily living [MG-ADL], and MG-QoL [15-item questionnaire] [MG-QoL15] scores) (Figures 1 and 2 ). Following a short discontinuation of eculizumab treatment in 2020 due to cost-associated challenges, the patient experienced MG regression, including a myasthenic crisis (Figures 1 and 2 ). However, the patient’s condition quickly improved (within 12 days) upon reinitiating eculizumab. In 2022, the patient switched from eculizumab to ravulizumab without any complications and is currently still being treated with bi-weekly ravulizumab and reduced steroid intake (Figures 1 and 2 ).